Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling

Seminars in Cell and Developmental Biology

Volumn 19, Issue 4, 2008, Pages 351-359

  Regis, Gabriella ^a   Pensa, Sara ^a   Boselli, Daniela ^a,b   Novelli, Francesco ^a,b   Poli, Valeria ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

gp130 cytokines; Interferons; Signalling; STAT1; STAT3

Indexed keywords

GLYCOPROTEIN GP 130; INTERFERON; INTERLEUKIN 10; JANUS KINASE; STAT1 PROTEIN; STAT3 PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; INFLAMMATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 52949136974     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.06.004     Document Type: Review

References (172)

1. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282 (2007) 20059-20063
2. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
3. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Ann Rev Biochem 67 (1998) 227-264
4. Schindler C., and Brutsaert S. Interferons as a paradigm for cytokine signal transduction. Cell Mol Life Sci 55 (1999) 1509-1522
5. Poli V., and Alonzi T. STAT3 function in vivo. In: Sehgal P.B.L.D., and Hirano T. (Eds). Signal transducers and activators of transcription (STATs): activation and biology (2003), Kluwer Academic Publishers, Dordrecht, Boston, London 493-512
6. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev 5 (2005) 375-386
7. Sato T., Selleri C., Young N.S., and Maciejewski J.P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood 90 (1997) 4749-4758
8. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., and Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 Pt 2 (1998) 297-314
9. Baker S.J., Rane S.G., and Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 26 (2007) 6724-6737
10. Sachsenmaier C., Sadowski H.B., and Cooper J.A. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Oncogene 18 (1999) 3583-3592
11. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 (2004) 163-189
12. Bernabei P., Coccia E.M., Rigamonti L., Bosticardo M., Forni G., Pestka S., et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 70 (2001) 950-960
13. Conti L., Regis G., Longo A., Bernabei P., Chiarle R., Giovarelli M., et al. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 109 (2007) 2496-2504
14. Miura Y., Tsujioka T., Nishimura Y., Sakaguchi H., Maeda M., Hayashi H., et al. TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res 26 (2006) 4115-4124
15. Choi E.A., Lei H., Maron D.J., Wilson J.M., Barsoum J., Fraker D.L., et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res 63 (2003) 5299-5307
16. Fulda S., and Debatin K.M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21 (2002) 2295-2308
17. Allione A., Bernabei P., Bosticardo M., Ariotti S., Forni G., and Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol 163 (1999) 4182-4191
18. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., and Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 (1996) 719-722
19. Dimberg A., Karlberg I., Nilsson K., and Oberg F. Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood 102 (2003) 254-261
20. Xiao S., Li D., Zhu H.Q., Song M.G., Pan X.R., Jia P.M., et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci USA 103 (2006) 16448-16453
21. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K.C., Williams B.R., et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 19 (2000) 263-272
22. Stephanou A., Brar B.K., Knight R.A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7 (2000) 329-330
23. Wang Y., Wu T.R., Cai S., Welte T., and Chin Y.E. Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol Cell Biol 20 (2000) 4505-4512
24. Townsend P.A., Scarabelli T.M., Davidson S.M., Knight R.A., Latchman D.S., and Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279 (2004) 5811-5820
25. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
26. Dechow T.N., Pedranzini L., Leitch A., Leslie K., Gerald W.L., Linkov I., et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101 (2004) 10602-10607
27. Azare J., Leslie K., Al-Ahmadie H., Gerald W., Weinreb P.H., Violette S.M., et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 27 (2007) 4444-4453
28. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 109 (2002) 1139-1142
29. Chapman R.S., Lourenco P.C., Tonner E., Flint D.J., Selbert S., Takeda K., et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13 (1999) 2604-2616
30. Lee C.K., Raz R., Gimeno R., Gertner R., Wistinghausen B., Takeshita K., et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17 (2002) 63-72
31. Barre B., Avril S., and Coqueret O. Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem 278 (2003) 2990-2996
32. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
33. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97 (2006) 439-447
34. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 110 (2002) 1503-1513
35. Billiau A. Interferon-gamma: biology and role in pathogenesis. Adv Immunol 62 (1996) 61-130
36. Dustin M.L., Singer K.H., Tuck D.T., and Springer T.A. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med 167 (1988) 1323-1340
37. Strieter R.M., Kunkel S.L., Arenberg D.A., Burdick M.D., and Polverini P.J. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 210 (1995) 51-57
38. Li S., Xia X., Mellieon F.M., Liu J., and Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9 (2004) 347-354
39. Baratin M., Ziol M., Romieu R., Kayibanda M., Gouilleux F., Briand P., et al. Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 8 (2001) 193-202
40. Xie K., Wang Y., Huang S., Xu L., Bielenberg D., Salas T., et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 15 (1997) 771-779
41. Chatterjee-Kishore M., Kishore R., Hicklin D.J., Marincola F.M., and Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 273 (1998) 16177-16183
42. Brucet M., Marques L., Sebastian C., Lloberas J., and Celada A. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. Genes Immun 5 (2004) 26-35
43. Marques L., Brucet M., Lloberas J., and Celada A. STAT1 regulates lipopolysaccharide- and TNF-alpha-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J Immunol 173 (2004) 1103-1110
44. Rouyez M.C., Lestingi M., Charon M., Fichelson S., Buzyn A., and Dusanter-Fourt I. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 174 (2005) 3948-3958
45. Muhlethaler-Mottet A., Di Berardino W., Otten L.A., and Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8 (1998) 157-166
46. Lee Y.J., and Benveniste E.N. Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol 157 (1996) 1559-1568
47. Agnello D., Lankford C.S., Bream J., Morinobu A., Gadina M., O'Shea J.J., et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23 (2003) 147-161
48. Williams L.M., Ricchetti G., Sarma U., Smallie T., and Foxwell B.M. Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology 113 (2004) 281-292
49. Donnelly R.P., Dickensheets H., and Finbloom D.S. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19 (1999) 563-573
50. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
51. Ito S., Ansari P., Sakatsume M., Dickensheets H., Vazquez N., Donnelly R.P., et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93 (1999) 1456-1463
52. Riley J.K., Takeda K., Akira S., and Schreiber R.D. Interleukin-10 receptor signaling through the JAK-STAT pathway, requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 274 (1999) 16513-16521
53. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999) 39-49
54. Williams L., Bradley L., Smith A., and Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172 (2004) 567-576
55. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004) 48-54
56. Gil M.P., Bohn E., O'Guin A.K., Ramana C.V., Levine B., Stark G.R., et al. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 98 (2001) 6680-6685
57. Arany I., Chen S.H., Megyesi J.K., Adler-Storthz K., Chen Z., Rajaraman S., et al. Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett 199 (2003) 83-89
58. Costa-Pereira A.P., Tininini S., Strobl B., Alonzi T., Schlaak J.F., Is'harc H., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci USA 99 (2002) 8043-8047
59. Tanabe Y., Nishibori T., Su L., Arduini R.M., Baker D.P., and David M. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol 174 (2005) 609-613
60. Qing Y., and Stark G.R. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 279 (2004) 41679-41685
61. Gimeno R., Lee C.K., Schindler C., and Levy D.E. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol 25 (2005) 5456-5465
62. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., and Poli V. Essential role of the Signal Transducer and Activator of Transcription STAT3 in the control of the acute phase response as revealed by inducible gene inactivation in the liver. Mol Cell Biol 21 (2001) 1621-1632
63. Barry S.P., Townsend P.A., Latchman D.S., and Stephanou A. Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 13 (2007) 82-89
64. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury. J Cell Mol Med 8 (2004) 519-525
65. Hilfiker-Kleiner D., Hilfiker A., and Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 107 (2005) 131-137
66. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., Kaminski K., Schaefer A., Schieffer B., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 95 (2004) 187-195
67. Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
68. Jacoby J.J., Kalinowski A., Liu M.G., Zhang S.S., Gao Q., Chai G.X., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100 (2003) 12929-12934
69. Stephanou A., Brar B.K., Scarabelli T.M., Jonassen A.K., Yellon D.M., Marber M.S., et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 275 (2000) 10002-10008
70. Atsumi T., Ishihara K., Kamimura D., Ikushima H., Ohtani T., Hirota S., et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 196 (2002) 979-990
71. de Hooge A.S., van de Loo F.A., Koenders M.I., Bennink M.B., Arntz O.J., Kolbe T., et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum 50 (2004) 2014-2023
72. Yokota A., Narazaki M., Shima Y., Murata N., Tanaka T., Suemura M., et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J Rheumatol 28 (2001) 1952-1959
73. Walters D.M., Antao-Menezes A., Ingram J.L., Rice A.B., Nyska A., Tani Y., et al. Susceptibility of signal transducer and activator of transcription-1-deficient mice to pulmonary fibrogenesis. Am J Pathol 167 (2005) 1221-1229
74. Hu X., Herrero C., Li W.P., Antoniv T.T., Falck-Pedersen E., Koch A.E., et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol 3 (2002) 859-866
75. Radaeva S., Jaruga B., Kim W.H., Heller T., Liang T.J., and Gao B. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochem J 379 (2004) 199-208
76. Herrero C., Hu X., Li W.P., Samuels S., Sharif M.N., Kotenko S., et al. Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol 171 (2003) 5034-5041
77. Sharif M.N., Tassiulas I., Hu Y., Mecklenbrauker I., Tarakhovsky A., and Ivashkiv L.B. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172 (2004) 6476-6481
78. Lauw F.N., Pajkrt D., Hack C.E., Kurimoto M., van Deventer S.J., and van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165 (2000) 2783-2789
79. Li W., Lu L., Li Y., Fu F., Fung J.J., Thomson A.W., et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc 29 (1997) 1081-1082
80. Rose R.W., Vorobyeva A.G., Skipworth J.D., Nicolas E., and Rall G.F. Altered levels of STAT1 and STAT3 influence the neuronal response to interferon gamma. J Neuroimmunol 192 (2007) 145-156
81. Gil M.P., Salomon R., Louten J., and Biron C.A. Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood 107 (2006) 987-993
82. Maritano D., Sugrue M.L., Tininini S., Dewilde S., Strobl B., Fu X., et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 5 (2004) 401-409
83. Chen X.P., Losman J.A., and Rothman P. SOCS proteins, regulators of intracellular signaling. Immunity 13 (2000) 287-290
84. Marine J.C., Topham D.J., McKay C., Wang D., Parganas E., Stravopodis D., et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98 (1999) 609-616
85. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98 (1999) 597-608
86. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 (2003) 540-545
87. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4 (2003) 546-550
88. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4 (2003) 551-556
89. Ilangumaran S., Ramanathan S., and Rottapel R. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 16 (2004) 351-365
90. Wormald S., Zhang J.G., Krebs D.L., Mielke L.A., Silver J., Alexander W.S., et al. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 281 (2006) 11135-11143
91. Ho H.H., and Ivashkiv L.B. Role of STAT3 in type I interferon responses, negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281 (2006) 14111-14118
92. Thyrell L., Arulampalam V., Hjortsberg L., Farnebo M., Grander D., and Pokrovskaja Tamm K. Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp Cell Res 313 (2007) 4015-4024
93. Kim H.S., and Lee M.S. STAT1 as a key modulator of cell death. Cell Signal 19 (2007) 454-465
94. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
95. Huang M., Page C., Reynolds R.K., and Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79 (2000) 67-73
96. Niu G., Bowman T., Huang M., Shivers S., Reintgen D., Daud A., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21 (2002) 7001-7010
97. Horiguchi A., Oya M., Shimada T., Uchida A., Marumo K., and Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168 (2002) 762-765
98. Zamo A., Chiarle R., Piva R., Howes J., Fan Y., Chilosi M., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (2002) 1038-1047
99. Corvinus F.M., Orth C., Moriggl R., Tsareva S.A., Wagner S., Pfitzner E.B., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (New York, NY) 7 (2005) 545-555
100. Chang K.C., Wu M.H., Jones D., Chen F.F., and Tseng Y.L. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol 210 (2006) 224-233
101. Regis G., Bosticardo M., Conti L., De Angelis S., Boselli D., Tomaino B., et al. Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. Blood 105 (2005) 3214-3221
102. Elahi A., Zhang L., Yeatman T.J., Gery S., Sebti S., and Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int J Cancer (2007)
103. Sanceau J., Hiscott J., Delattre O., and Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19 (2000) 3372-3383
104. Kumar A., Commane M., Flickinger T.W., Horvath C.M., and Stark G.R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278 (1997) 1630-1632
105. Egwuagu C.E., Li W., Yu C.R., Che Mei Lin M., Chan C.C., Nakamura T., et al. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25 (2006) 3670-3679
106. Gansauge S., Nussler A.K., Beger H.G., and Gansauge F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ 9 (1998) 611-617
107. Chlichlia K., Peter M.E., Rocha M., Scaffidi C., Bucur M., Krammer P.H., et al. Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 91 (1998) 4311-4320
108. Ushmorov A., Ratter F., Lehmann V., Droge W., Schirrmacher V., and Umansky V. Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. Blood 93 (1999) 2342-2352
109. Ho Y.S., Wang Y.J., and Lin J.K. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog 16 (1996) 20-31
110. Thomas M., Finnegan C.E., Rogers K.M., Purcell J.W., Trimble A., Johnston P.G., et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 64 (2004) 8357-8364
111. Youlyouz-Marfak I., Gachard N., Le Clorennec C., Najjar I., Baran-Marszak F., Reminieras L., et al. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ 15 (2008) 376-385
112. Burke F., Smith P.D., Crompton M.R., Upton C., and Balkwill F.R. Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA. Br J Cancer 80 (1999) 1236-1244
113. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
114. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97 (2000) 4227-4232
115. Turkson J., Zhang S., Palmer J., Kay H., Stanko J., Mora L.B., et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3 (2004) 1533-1542
116. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11 (2005) 623-629
117. Sun Z., Yao Z., Liu S., Tang H., and Yan X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 211 (2006) 199-209
118. Gao L.F., Wen L.J., Yu H., Zhang L., Meng Y., Shao Y.T., et al. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin 27 (2006) 347-352
119. Li W.C., Ye S.L., Sun R.X., Liu Y.K., Tang Z.Y., Kim Y., et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12 (2006) 7140-7148
120. Jing N., Li Y., Xiong W., Sha W., Jing L., and Tweardy D.J. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 64 (2004) 6603-6609
121. Jing N., Zhu Q., Yuan P., Li Y., Mao L., and Tweardy D.J. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 5 (2006) 279-286
122. Zhang X., Zhang J., Wang L., Wei H., and Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7 (2007) 149
123. Hellsten R., Johansson M., Dahlman A., Dizeyi N., Sterner O., and Bjartell A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 68 (2008) 269-280
124. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H.R., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104 (2007) 7391-7396
125. Molavi O., Ma Z., Mahmud A., Alshamsan A., Samuel J., Lai R., et al. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 347 (2008) 118-127
126. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev 7 (2007) 41-51
127. Niu G., Wright K.L., Ma Y., Wright G.M., Huang M., Irby R., et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25 (2005) 7432-7440
128. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
129. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
130. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22 (2003) 1517-1527
131. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24 (2005) 5552-5560
132. Bartoli M., Platt D., Lemtalsi T., Gu X., Brooks S.E., Marrero M.B., et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 17 (2003) 1562-1564
133. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278 (2003) 40026-40031
134. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 (2004) 3550-3560
135. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25 (2006) 1195-1204
136. Song Y., Qian L., Song S., Chen L., Zhang Y., Yuan G., et al. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol Immunol 45 (2008) 137-143
137. Silver D.L., Naora H., Liu J., Cheng W., and Montell D.J. Activated signal transducer and activator of transcription (STAT) 3, localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64 (2004) 3550-3558
138. Holling T.M., Bergevoet M.W., Wilson L., Van Eggermond M.C., Schooten E., Steenbergen R.D., et al. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol 179 (2007) 5317-5325
139. Prod'homme T., Drenou B., De Ruyffelaere C., Barbieri G., Wiszniewski W., Bastard C., et al. Defective class II transactivator expression in a B lymphoma cell line. Leukemia 18 (2004) 832-840
140. Croce M., De Ambrosis A., Corrias M.V., Pistoia V., Occhino M., Meazza R., et al. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene 22 (2003) 7848-7857
141. Critchley-Thorne R.J., Yan N., Nacu S., Weber J., Holmes S.P., and Lee P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4 (2007) e176
142. Kusmartsev S., and Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174 (2005) 4880-4891
143. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
144. Torrero M.N., Xia X., Henk W., Yu S., and Li S. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 66 (2006) 4461-4467
145. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev 6 (2006) 836-848
146. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272 (1997) 28779-28785
147. Xi S., Dyer K.F., Kimak M., Zhang Q., Gooding W.E., Chaillet J.R., et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst 98 (2006) 181-189
148. Cheng F., Wang H.W., Cuenca A., Huang M., Ghansah T., Brayer J., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19 (2003) 425-436
149. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11 (2005) 1314-1321
150. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174 (2005) 3925-3931
151. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95 (1998) 7556-7561
152. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
153. Fallarino F., and Gajewski T.F. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163 (1999) 4109-4113
154. Lesinski G.B., Anghelina M., Zimmerer J., Bakalakos T., Badgwell B., Parihar R., et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112 (2003) 170-180
155. Kovacic B., Stoiber D., Moriggl R., Weisz E., Ott R.G., Kreibich R., et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10 (2006) 77-87
156. Lin W., Kemper A., McCarthy K.D., Pytel P., Wang J.P., Campbell I.L., et al. Interferon-gamma induced medulloblastoma in the developing cerebellum. J Neurosci 24 (2004) 10074-10083
157. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
158. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
159. Leong P.L., Andrews G.A., Johnson D.E., Dyer K.F., Xi S., Mai J.C., et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100 (2003) 4138-4143
160. Konnikova L., Kotecki M., Kruger M.M., and Cochran B.H. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 (2003) 23
161. Sun X., Zhang J., Wang L., and Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett (2008)
162. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114 (2004) 720-728
163. Chan K.S., Sano S., Kataoka K., Abel E., Carbajal S., Beltran L., et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene (2007)
164. Li Y., Du H., Qin Y., Roberts J., Cummings O.W., and Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 67 (2007) 8494-8503
165. de la Iglesia N., Konopka G., Puram S.V., Chan J.A., Bachoo R.M., You M.J., et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008)
166. Lui V.W., Boehm A.L., Koppikar P., Leeman R.J., Johnson D., Ogagan M., et al. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT), 3 the role of STAT1. Mol Pharmacol 71 (2007) 1435-1443
167. Haura E.B., Turkson J., and Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract 2 (2005) 315-324
168. Bernabei P., Allione A., Rigamonti L., Bosticardo M., Losana G., Borghi I., et al. Regulation of interferon-gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes. Eur Cytokine Netw 12 (2001) 6-14
169. Kiil Blomhoff H., Davies C., Ruud E., Funderud S., and Godal T. Distinct effects of gamma interferon on human B-lymphocyte precursor cell lines. Scand J Immunol 22 (1985) 611-617
170. Tomita Y., Cantell K., and Kuwata T. Effects of human gamma interferon on cell growth, replication of virus and induction of 2′-5′oligoadenylate synthetase in three human lymphoblastoid cell lines and K562 cells. Int J Cancer 30 (1982) 161-165
171. Kim E.J., Lee J.M., Namkoong S.E., Um S.J., and Park J.S. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 85 (2002) 369-380
172. Massad L.S., Mutch D.G., Powell C.B., Kao M.S., and Collins J.L. Expression of a resistance mechanism in ovarian and cervical carcinoma cells prevents their lysis by gamma-interferon. Cancer Res 50 (1990) 4923-4928